








Disease Monograph Series – 14 








Bovine Babesiosis | Monograph 14 













This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre (IDRC) over the period Nov 2015 to April 
2016 to inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The 
LVIF is a seven-and-a-half year, CA$57 million partnership between the Bill & Melinda 
Gates Foundation, Global Affairs Canada and Canada’s International Development 
Research Centre. It focuses on those animal diseases posing the greatest risk to poor 
livestock keepers in Sub-Saharan Africa, South and Southeast Asia, targeting 
transboundary diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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ACIAR  Australian Center for International Agricultural Research 
AI  Avian influenza 
APMV  Avian paramyxovirus 
AU  African Union 
AU-IBAR African Union InterAfrican Bureau For Animal Resources 
AU PANVAC AU Pan African Veterinary Vaccine Centre 
BSL-3  Biosafety level 3 (Laboratory designation required for challenge studies) 
DIVA   Differentiating infected from vaccinated animals (strategy) 
ELISA  Enzyme-linked immunosorbent assay 
FAO  Food and Agriculture Organization of the United Nations 
H  Hemagglutinin  
HA  Hemagglutinin antigen 
HI  Hemagglutinin inhibition 
HN  Hemagglutinin-neuraminidase 
  
Bovine Babesiosis | Monograph 14 








Etiology and relevance 
Bovine babesiosis, or redwater is a tick-borne disease caused by the intra-erythrocytic protozoan parasite 
Babesia. Only two Babesia species, B. bovis and B. bigemina, are important and widespread in tropical and 
subtropical countries. Although morphologically different, B. bovis being smaller than B. bigemina, the two 
species show variations that make it sometime difficult to discriminate among them.   
  
Epidemiology and transmission 
The lifecycle of the Babesias involves ticks and cattle. In ticks, their different forms and stages invade all tick’s 
organs, including the ovaries, and insure passage to next generations of ticks. Babesia are maintained in cattle 
populations by asymptomatic carriers that have recovered from acute disease. B. bovis persists in cattle for 
years, and B. bigemina survives for a few months. Recrudescence of parasitemia can occur at irregular intervals. 
Babesia species are transmitted by ticks, which become infected when they ingest parasites in the blood of 
infected cattle.   
The major vectors for B. bigemina and B. bovis are Rhipicephalus microplus (formerly Boophilus microplus) and 
R. annulatus (formerly B. annulatus). Other tick species, Rhipicephalus and others, can also transmit the two 
parasites. Bovine babesiosis can be found wherever the tick vectors exist, but it is most common in tropical and 
subtropical areas. B. bovis and B. bigemina are particularly important in Asia, Africa, Central and South America, 
parts of southern Europe, and Australia. R. microplus has recently been introduced to West Africa with cattle 
imported from Latin America and has been spreading at an alarming rate, with no measures being taken to curb 
the problem. There is however not yet enough evidence to support the possibility of subsequent spread of 
bovine babesiosis.  
B. bovis and B bigemina affect cattle, which are the main reservoir hosts. They also affect water buffalo and 
African buffalo. Bovine Babesiosis is predominantly observed in adult cattle. Without treatment, mortality rates 
are very high (30% for Babesia bigemina, 70-80% for B. bovis). Calves can be infected in utero; however, this 
appears to require pathological changes in the placenta, and transplacental infection seems to be accidental and 
rare.  
Very few studies exist on the different target countries and economic impact of bovine babesiosis; most of the 
information is on the overall impact of tick borne diseases (TBD). In East Africa for example, the importance and 
impact of bovine babesiosis is somehow obscured by that of Theileriosis. From the limited studies conducted to 
date, Minjauw et al. (2003), quoting a 1999 study, gave an estimated annual cost of bovine babesiosis in India of   
USD 57.2 million. In one of the few studies published in Africa, Kivaria’s (2006) estimated the combined annual 
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direct costs associated with Babesiosis in Tanzania to be 45.8million USD, the third most important TBD after 
ECF and Anaplasmosis.  
Reports on low prevalence and incidence for bovine babesiosis are considered to be underestimates, generally 
linked to the overwhelming focus on diseases like ECF in East and Southern Africa, the focus on ticks, which are a 
major and increasing problem in all countries covered in this report, poor diagnostic capacity and reporting that 
covers TBD as a group.   
 
Clinical disease and diagnostic  
Infections with Babesia spp. are characterised by a haemolytic syndrome which includes continuous fever, high 
parasitaemia, anaemia, icterus and often haemoglobinuria, which colours the urine dark brown and which gives 
the disease the common name of ‘red water’. Infections associated with B. bovis are often acute or subacute, 
rapidly leading to death. Acute disease can cause nervous symptoms such as ‘pedalling’ movements and 
aggressive behaviour. In dairy cows, abortion and agalactia are early signs of infection.   
Babesiosis can be diagnosed by identification of the parasites in blood or tissues, PCR, serology, or transmission 
experiments. In the case of B. bovis, a diagnosis of babesiosis can be confirmed by the presence of the parasites 
in Giemsa-stained blood smears. However, the presence of B. bigemina in a blood smear does not necessarily 
indicate babesiosis, as symptoms could be due to the resurgence of a chronic infection caused by another 
disease. Infected animals develop a life-long immunity against re-infection with the same species and some 
crossprotection is evident in B. bigemina-immune animals against subsequent B. bovis infections.  
  
Control 
Control of bovine babesiosis relies on tick control, chemotherapy/treatment, possibly the use of the use of 
tickresistant breeds of cattle and immunisation. The most widely available and effective drugs for the treatment 
of bovine babesiosis are diminazine aceturate and imidocarb dipropionate. The latter is an effective therapeutic 
agent for both anaplasmosis and babesiosis which also has prophylactic activity, and often is used to treat both 
diseases. Tick control, together with treatment, are the most widely used strategies in controlling bovine 
babesiosis in Asia and Africa.    
Early bovine babesiosis immunization utilised infected blood collected from recovered animals—the so-called 
carrier donor system, and injected into young, relatively insusceptible calves, leading in most cases to a mild 
fever and subsequent immunity to what otherwise may have been a lethal natural challenge arising when 
animals were exposed to tick-infested pastures. The high variability in their infectivity and high virulence risk 
brought scientists in Australia to develop attenuated strains, through passage in splenectomised calves.  The 
currently used blood vaccines are produced in splenectomised calves, which are inoculated with a stock of the 
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attenuated B. bovis and B. bigemina parasites, and bled during the acute phase of the reaction, to produce, with 
the collected blood, a standardized vaccine.   
Most of the available live vaccines are produced in government-supported production facilities, notably in 
Australia, Argentina, South Africa, Israel and Uruguay. Of the target countries, only South Africa uses the bovine 
babesiosis vaccines, which are produced by the OVI and commercialised by OBP. The initial attenuated vaccines 
were chilled. But due to their short shelf life, a frozen form is now produced by OBP and many other countries, 
while Australia still produces the chilled form. Some manufacturers also have combination vaccines, including 
the two Babesia and Anaplasma. OBP produces the two babesia vaccines separately.  
Since 1994, a vaccine with efficacy against the cattle tick, R. microplus, the major vector of bovine babesias, was 
developed, patented and marketed in Australia under the name TickGARD using the midgut glycoprotein antigen 
Bm86. A number of industrial consolidations produced unfavourable outcomes for TickGARD and it is no longer 
commercially available. A similar vaccine using basically the same antigen and oil adjuvanted was developed in 
Cuba in the 1990s, under the trade name Gavac, and is still being commercialised in North and Latin America. 
Review studies on the use of these two vaccines indicate that they have been effective in controlling B. 
microplus, resulting in subsequent decrease in acaricide usage and reductions in anaplasmosis and babesiosis. 
None of the tick vaccines is used in Africa and Asia.   
 
The future of bovine baesiosis vaccines and vaccination 
Of the countries targeted in the present monograph, only South Africa uses vaccination, with the only form 
currently available: the live attenuated bovine babesiosis vaccines produced in splenectomised animals. While 
they provide a good protection in immunized animals, their wide use is limited due to the complex and risky 
production process involving live animals, the requirement for strict cold chain and need for close veterinary or 
specialized supervision during administration. The poor results obtained with non-replicating vaccines and the 
discontinued efforts indicate that there may not be an alternative vaccine in the short to medium term. None of 
the Asian countries have been producing or using babesia live attenuated vaccines.   
  
Options that could be considered in the meantime are:  
1. Further improvement of the current live attenuated vaccine: aspects to be considered would 
include cell culture, freeze-drying, combination of both B. bovis and B. bigemina in Africa.   
2. Combination with other TBD like Anaplasma, already practiced in Latin America could be 
considered given the common occurrence of these diseases.  
3. Given the limited efficacy of inactivated vaccines, a vaccination program consisting of priming 
with inactivated vaccine and boosting with live one could be considered and evaluated as it may 
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address the safety problems of the live vaccine, while aiding in the buildup of a solid long lasting 
immunity.  
4. There is a need to consider a broader use of the R. microplus tick vaccine in more regions in 
Africa and Asia. Although there is not yet evidence that the spread of the R. microplus tick in West 
Africa has corresponded to a worsening of Babesiosis, it will be critical to consider starting to deal 
with the problem before the parasite get established. Such vaccine could also be a way of 
addressing the worsening tick resistance problem in Africa.   
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Bovine babesiosis or redwater is a tick-borne disease 
caused by the intra-erythrocytic protozoan parasite 
Babesia. Two species are economically important in 
tropical and subtropical regions of the world, 
including southern Africa: Babesia bovis, which causes 
Asiatic (European) redwater, and Babesia bigemina, 
which causes African redwater. Babesia divergens 
causes an economically important disease in the 
British Isles and northern Europe [9][25].  
 
The present monograph will focus on Bovine 
babesiosis caused by B. bovis and B. bigemina.  In the 
US situation it is referred to as Tick Fever, Cattle Fever 




The parasite Babesia is named after Babes, the 
scientist who first described it in sheep and cattle in 
1888 [9]. The genus Babesia belongs to the phylum 
Apicomplexa, class Sporozoasida, order 
Eucoccidiorida, suborder Piroplasmorina and family 
Babesiidae [2]. The Babesia spp. known to infect cattle 
in southern Africa, and their proven vectors, are listed 
in Table 1.  
Parasite structure 
Organisms belonging to the genus Babesia are pear-shaped 
and parasitize red blood cells of mammals and invade the 
internal organs of ticks.  Babesia bovis is classically known 
as a 'small' Babesia measuring up to 2 µm in diameter, 
while B. bigemina is larger and can extend to the full 
diameter of an erythrocyte. However, the two species both 
show considerable morphological variation, making it 
difficult to identify one from the other. Large forms of B. 




Figure 1:  Schematic representation of a bovine Red 
Blood Cell parasitised by a mature form of Babesia 
bovis (22) 
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Table 1: Bovine Babesia spp. and their vectors in southern Africa [9]  
 
Babesia spp. Vectors 
Babesia bovis  Rhipicephalus(Boophilus) microplus  
Babesia bigemina   Rhipicephalus (B.)decoloratus  
Rhipicephalus microplus  
Rhipicephalus evertsi evertsi  
Babesia occultans  Hyalomma marginatum rufipes  
  






Susceptible animal species   
Babesia bovis and B. bigemina have high degrees of host specificity: they are found in cattle, which are the main 
reservoir hosts. They also affect water buffalo (Bubalus bubalis) and African buffalo (Syncerus caffer).  
In Africa, European, Sanga and Zebu breeds are all known to be susceptible, and all develop latent infections 
after recovery which persists for various lengths of time [9]. European breeds of cattle can retain B. bovis 
infections for life and remain infective for ticks for up to two years [5] while most cattle with a significant Zebu 
content lose the infection within two years. Babesia bigemina infections rarely persist for more than a year, 
regardless of the host, and infected cattle remain infective for ticks for only four to seven weeks.  
African buffalo (Syncerus caffer) and Asiatic buffalo (Bubalus bubalis) can develop latent infections [9]. Antibodies 
and transitory infections have also been demonstrated in other animals, but there is little evidence to suggest 
that non familiarhosts are important reservoir hosts even though R. e. evertsi infected with B. bigemina have 
been collected off a sable antelope (Hippotragus niger) with clinical babesiosis.  
  
 
Transmission and Vectors of Bovine Babesiosis  
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Babesia species are transmitted by ticks, which become infected when they ingest parasites in the blood of 
infected cattle. The major vectors for B. bigemina are Rhipicephalus microplus (formerly Boophilus microplus) 
and R. annulatus. R. decoloratus, R. geigyi, and R. evertsi can also transmit this species [5][9]. The major vectors 




Figure 2: Babesia bovis life cycle (Mosqueda et al.; 2012) 
 
Inside the tick, Babesia zygotes multiply as ‘vermicules,’ which invade many of the tick’s organs including the 
ovaries; Babesia species are readily passed to the next generation of ticks in the egg. These parasites can 
sometimes be passed transovarially though several generations, although this varies with the species of Babesia 
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and the species of tick. B. divergens can survive in tick populations for at least 4 years even if cattle are not 
present. When an infected tick attaches to a new host, Babesia are stimulated to undergo their final maturation. 
B. bovis parasites usually become infective within 2-3 days after larval ticks attach, and can be transmitted by 
larvae. In R. microplus, B. bovis does not persist after the larval stage. In contrast, B. bigemina matures in 
approximately 9 days after a larval tick attaches, and it is only transmitted by nymphs and adults [5].   
Babesia species can also be transmitted between animals by direct inoculation of blood. Biting flies and fomites 
contaminated by infected blood might act as mechanical vectors, although this method of transmission is 
thought to be of minor importance.   
Babesia are maintained in cattle populations by asymptomatic carriers that have recovered from acute disease. 
B. bovis persists in cattle for years, and B bigemina survives for a few months. Recrudescence of parasitemia can 
occur at irregular intervals. Calves can be infected in utero; however, this appears to require pathological 
changes in the placenta, and transplacental infection seems to be accidental and rare.  [9][24]  
Inter-specific mating may occur between B. microplus and B. decoloratus, resulting in the production of sterile 
eggs and the creation of a ‘hybrid zone’ where populations of the two species overlap [5][9].  
This zone may have prevented B. microplus from fully exploiting all the climatologically favorable areas in the 
subcontinent. Its width and stability are unknown, but it is likely to have a significant effect on the epidemiology 
of B. bovis. Babesia bigemina’s lack of vector specificity makes it unlikely that this species will be affected by 
competition between tick species.  
One infected larval tick is sufficient to transmit B. bovis, but tick infection rates are usually low and the rate of 
transmission to cattle is therefore low. Tick infection rates with B. bigemina are higher (0,23 per cent in the 
Australian study) and therefore transmission rates of this species are also higher than those of B. bovis. As a 
result, B. bigemina infections are usually more prevalent in those herds where both species are present and less 
readily affected by factors such as climate or management, which reduce tick numbers [9].  
  
Distribution  
Bovine babesiosis can be found wherever the tick vectors exist, but it is most common in tropical and subtropical 
areas.    
Based on CABI summary report (http://www.cabi.org/isc/datasheet/91606) R. microplus is originally from Asia 
and has been distributed, mainly with cattle, to all continents. The tick occurs in South and Central America, 
including Mexico, and is a major problem in Brazil. It occurs in much of southern Asia and also in China. The tick 
was introduced into East and South Africa from Madagascar, where it had originally arrived with cattle from 
southern Asia. In South Africa it is now established in scattered areas along the southern and eastern costs of 
the Western and Eastern Cape Provinces and of KwaZulu-Natal. R. microplus is also present in the coastal 
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regions of Mozambique, Kenya and Tanzania. The tick is spreading westwards in parts of southern (Zambia, 
Zimbabwe) and East Africa.   
As discussed later in this document, R. microplus has since been introduced in West Africa and has been 
spreading at an alarming rate as far as Central Africa, with reports in Cameroon (1, Dr. Adakal personnal 
communication). But so far there is not enough evidence of a concurrent spread of Bovine babesiosis.  
B. bovis and B. bigemina are particularly important in Asia, Africa, Central and South America, parts of southern 
Europe, and Australia. Although B. bovis is usually found in the same general geographic area as B. bigemina, 
slightly different groups of ticks spread these two species and some differences in their distribution can be seen. 
For example, B. bigemina is more widely distributed than B. bovis in Africa. B. bigemina and B. bovis and their 
vectors were formerly enzootic throughout much of the southern United States, but now are found only in a 
quarantine buffer zone along the Mexican border [24][26]. See Table 2.   
 
Table 2: Bovine Babesia spp. and their vectors in southern Africa [9]  
 
Organism  Animals affected  Geographical distribution  
Babesia bigemina  Cattle, Zebu, Water buffalo 
Deer; Wild ruminants  
Central and South America Australia Africa Southern 
Europe China  
Babesia bovis  Cattle; Reindeer; Stag; Water 
buffalo, wild ruminants  





The distribution of the two pathogens in Africa is, as elsewhere aligned to that of the vectors, as shown in the 
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Introduction and spread of R. microplus in West Africa:  
• Over the past 10 years there have been an alarming spread and displacement of other ticks by R. microplus 
that is believed to have been introduced in the region from importation of cattle from Latin America [1] 
• In contrast, the increased reporting on the spread of the tick has not corresponded to an increase in the 
number of outbreaks in the region (Personal communication Dr. Hassane Adakal), as illustrated by the OIE 
and AU-IBAR reports for the last 10 years.  
  
Immunology  
The mechanisms of immunity to babesial parasites are hypothesized to require innate as well as adaptive 
responses [7]. Innate immunity is non-specific and includes factors such as host–parasite specificity, genetic 
factors, age of the host and the response of host cells (such as the mononuclear phagocyte system and 
polymorphonuclear leukocytes). Most Babesia spp. are highly host specific and often splenectomy is needed to 
establish an infection in an unnatural host [5][6]. This is the basis for the production of the current live attenuated 
vaccine.  
Two months old or younger calves born to previously unexposed cows are susceptible to infection and the 
effects of the disease, while offspring of immune mothers are resistant, presumably because of a passive 
transfer of immunity via the colostrum. After the age of two months a natural, non-specific, innate resistance, 
which persists for at least a further four to six months and is not dependent on the immune status of the cow, 
protects calves [9].  
The mechanisms of immunity in babesiosis are complex and involve both antibody and cell-mediated 
components. Antibodies develop after infection, but not all are protective and attempts to correlate antibody 
levels with immunity have failed [7].  Live B. bovis inoculated into cattle induces antibodies that remain at high 
levels for at least six months. These antibodies are strain specific96 and are of the IgM and IgG1 isotype [9].  
Specific and non-specific cell-mediated mechanisms involving T lymphocytes and natural killer (NK) cells appear 
to be involved in laboratory Babesia infections: intracellular death of parasites occurs which is not caused by 
antibodies and which is non-specific with other parasites, micro-organisms and even microbial extracts exerting 
the same effect on rapidly dividing Babesia organisms.  
Macrophages are important for immunity to B. bovis because they act as antigen-presenting cells (APC) for T 
helper (Th) lymphocytes and remove parasitized erythrocytes by phagocytosis. Macrophages activated by 
interferon-gamma are thought to play a significant role in resistance to B. bovis by parasite suppression via 
secretory products released from macrophages [7].  
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In natural infections, incubation periods usually vary from 8 to 15 days. In acute manifestations, fever (>40°C) is 
usually present for several days before the onset of other clinical signs: inappetence, depression, weakness and 
reluctance to move. Haemoglubinuria is often present especially in B. bigemina infections (hence the common 
name "redwater"). Anaemia and icterus are especially obvious ion more protracted cases. Diarrhoea is common 
and pregnant cows may abort. Cerebral babesiosis, which occasionally develops in B. bovis infections, is 
manifested by hyperaesthesia, nystagmus, circling, head pressing, aggression, convulsions and paralysis; these 
signs may or may not accompany other signs of acute babesiosis [6][9][24]. Without treatment, mortality rates are 
very high (30% for B. bigemina, 70-80% for B. bovis) [19][24].  
Necropsy of uncomplicated ("typical") cases of babesiosis is characterised by light red, watery blood and the 
mucous membranes and carcasses are paler than normal (these changes are due to anaemia). In many cases this 
pallor may be masked by icterus. Other findings include: enlarged and congested spleen, swollen friable and 
yellowish-brown liver, mottled appearance of the hepatic surface, distanded gall-bladder with viscous bile. The 
intestinal content is usually diminished (anorexia) and yellowish in colour (bile-stained). The kidneys are mildly 
to moderately swollen and dark reddish-brown in colour (haemoglobinuric nephrosis). The lungs are often 
oedematous, with foam present in the bronchi and trachea (probably due to agonal left heart failure). The heart 
is usually flabby and pale (degeneration, anaemia). The urine is discoloured and may be deep yellow to yellow-
brown (bilirubinuria) or a clear port-wine colour (haemoglobinuria) [9].   
Important to note that the above description of the macroscopic lesions applies not only to typical cases of 
babesiosis but to any disease in which significant erythrolysis occurs, hence the need for differential diagnosis 
taking into account other factors.  Table 3 below summarises the major clinical signs of bovine babesiosis for B. 
bigemina and B.bovis  .  
Table 3: Clinical signs for B. bovis and B. bigemina (adapted from [6][9][26] ) 
 
B. bovis  B. bigemina  
High fever  Fever is less of a feature  
Parasitaemia (percentage of infected erythrocytes) - maximum 
parasitaemia is often less than one per cent.  
 In B. bigemina parasitaemia often exceeds 10 per 
cent and may be as high as 30 per cent  
Neurologic signs such as incoordination, teeth grinding and 
mania. Some cattle may be found on the ground with the 
involuntary movements of the legs. When the nervous 
symptoms of cerebral babesiosis develop, the outcome is 
almost always fatal.  
Central nervous system (CNS) signs are uncommon 
Animals likely to separate from herd, be weak, 
depressed and reluctant to move   
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Dark coloured urine  Haemoglobinuria and anaemia Dark coloured urine  
Anorexia  Anorexia  
Lesions include enlarged soft and pulpy spleen, swollen liver, 
gall bladder distended with thick granular bile, congested 
dark-coloured kidneys and generalised anaemia and jaundice. 
Other organs may show congestion or petechial haemorrhages 
and occasionally there will be pulmonary oedema. Acute cases 
will show haemoglobinuria, but this may be absent in subacute 
or chronic cases. Clinical pathology centres on a haemolytic 
anaemia, which is characteristically macrocytic and 
hypochromic.  
The pathogenic effects relate more directly to 
erythrocyte destruction. Haemoglobinuria is present 
earlier and more consistently than in B. bovis 
infections. Acutely affected cattle are usually not as 
severely affected as those with B. bovis infections. In 
some cases the disease can develop very rapidly 
with sudden and severe anaemia, jaundice and 







Differential Diagnosis  
Babesiosis resembles other conditions that cause fever, and hemolytic anemia. The differential diagnosis 
includes anaplasmosis, trypanosomiasis, theileriosis, bacillary hemoglobinuria, leptospirosis, eperythrozoonosis, 
rapeseed poisoning and chronic copper poisoning. Rabies and other encephalitides may also be considerations 
in cattle with CNS signs [9][24]  
  
Laboratory diagnosis  
Laboratory diagnostics could be done either by blood smear, serology or using molecular techniques:  
Blood smears: given the fact that babesia spp. parasites only develop in red blood cells, thin blood films made 
from capillary blood are preferred; although thick blood films may be more sensitive, species differentiation is 
more difficult. Blood of the general circulation may contain up to 20 times fewer B. bovis than capillary blood. In 
B. bigemina infections, parasitized cells are evenly distributed throughout the blood circulation. B. bovis 
parasitaemias are often low (<0.1%), even at the peak of the reaction, while B. bigemina parasites are usually 
more numerous and therefore easy to detect [9][26].   
ELISAs have replaced the indirect fluorescent antibody (IFA) test as the most widely used test for the detection 
of antibodies to Babesia spp., because of processing efficiency and objectivity in interpretation of results. The 
IFA test has been used for detection of antibodies to B. bigemina, but serological cross-reactions make species 
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diagnosis difficult. The complement fixation (CF) test has also been used to detect antibodies against B. bovis 
and B. bigemina [26].  
The OIE Manual reports that a number of other tests have been developed in recent years, including the slide 
ELISA, latex and card agglutination tests and an immunochromatographic test. These tests show acceptable 
levels of sensitivity and specificity for B. bovis and, in the case of the dot ELISA, also for B. bigemina. However, 
none of these tests appears to have been adopted for routine diagnostic use in laboratories other than those in 
which the original development and validation took place. Adaptability of these tests to routine diagnostic 
laboratories is therefore unknown [26].  
The OIE also reports that a number of PCR techniques have been described for the detection and differentiation 
of Babesia species in carrier infections, as well as for differentiation of isolates of B. bovis. The application of the 
reverse line blot procedure, in which PCR products are hybridised to membranebound, species-specific 
oligonucleotide probes, to Babesia and, more recently, two quantitative PCR methods have enabled the 
simultaneous detection of multiple species, even in carrier state infections. However, current PCR assays 
generally do not lend themselves well to large-scale testing and at this time are unlikely to supplant serological 
tests as the method of choice for epidemiological studies. PCR assays are useful as confirmatory tests and in 
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Reports of the occurrence of Babesiosis specifically are not always made by many countries and often are 
grouped into reports of TBDs. Furthermore in East Africa Babesiosis as other TBD are masked by ECF clinically 
but also not often diagnosed. Most data are the result of research projects.  
  
 
Table 4: Number of Bovine Babesiosis outbreaks reported to the OIE between 2005-2015 (Numbers given 
only for the target countries). Source: OIE.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail  
 
Country  2005  2006  2007  2008  2009  2010  2011  2012  2013  2014  2015  
    Asia       
Bangladesh 0  0  0  0  0  0  0  0  0  0  0  
India 36  26  45  48  130  128  131  121  181  274  0  
Indonesia                       
Myanmar (Burma) 0  0  1  1  6  8  27  23  46  22  0  
Nepal 4  20  8  0  0  48  79  0  0  68  8  
Vietnam ?  ?  ?  ?  ?  ?  ?  ?  ?  0  0  
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    West Africa       
Burkina Faso 0  0  0  0  0  0  0  0  0  0  0  
Ivory Coast 1  0  0  0  0  0  0  0  0  0  0  
Mali 0  0  ...  ...  +..  ...  ...  ...  ...  ...  ...  
Senegal ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  
    East Africa       
Ethiopia  +  0  0  +  +  +  +  +  +  0  0  
Kenya  ?  +..  ?  +..  ?  4  +..  +..  ?  5  0  
Rwanda    +..  +..  +..  +..  +..  +..  +  +..  …  …  
Tanzania  10  29  184  56  33  36  27  12  18  20  7  
Uganda  +..  +..  +..  +..  +..  +..  +..  +..  +..  +..    
    Southern Africa       
Madagascar  0  0  0  +  +  4  10  8  13  7  0  
Malawi  3  2  5  4  3  4  2  3  1  0  0  
Mozambique  6  19  4  2  3  6  1  2  3  15  0  
South Africa  195  97  73  85  73  91  59  37  16  28  0  
Zambia  0  38  35  64  130  108  0  38  78  74  0  
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2- AU-IBAR:  The number of outbreaks reported to AU-IBAR is included in the Pan African Animal Resources Year 
Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=) and can be 
seen for the countries of interest in Table 5 below.    
Table 5: Number of Bovine Babesiosis outbreaks reported to the AU-IBAR from 2005 to 2015 (numbers 
given only for the target countries). Source: AU-IBAR Year Books.  
 
Country  2005*  2006**  2007  2008  2009  2010  2011  2012  2013  2014  2015  
    West Africa       
Burkina Faso                       
Ivory Coast                       
Mali                       
Senegal       1                
    East Africa       
Ethiopia       9      1          




26  24  2  5    
Rwanda                       




  25  12  19  22    
Uganda       7  11  4            
    Southern Africa       




  3          
Malawi     5          3        
Mozambique   5  6  2  4  7  2  2  6  2    
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South Africa   90  85  87  42  119    89  40  42    
Zambia     36  221 
cases  
22  571 
cases  
43  24  67  92    
 
 
*AU-IBAR didn’t start yet producing data for bovine babesiosis  






Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  
2014  Rangpur district  Cattle  400  Gangachara: 1.3%  
Pirgachaupazilas: 1.7%  








Sylhet district  Cattle  100  16% B. bigemina  Chandra Nath et 
al, 2013  
2009- 
2010  
Chittagong  Cattle  Crossbred: 216 
Indigenous: 432  
Crossbred: 9.25% 
Indigenous: 7.17%  
Alim et al, 2012  
2004  Sirajgong  Clinically 
suspected 
cattle  
60  3.3%  
B. bigemina  
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Year  Area  Species  of  
animal  
No. of samples 
tested  
% positive  Reference  
2015  Central plain zone of 
Punjab  
Cattle  204  2.45%  
B. bigemina  
Bhat et al, 2015  
2013  Three  states  of  
North-eastern  
India  
Cattle suspected for  
haemoprotoxoan  
333  3.60%  
B. bigemina  
Laha et al, 2015  
2013  National Research 
Centre on Yak,  
Yak  94  5.32%  
B. bigemina  
Saravanan et al, 
2013  
 Dirang, Arunachal 
Pradesh  
    
2012  Southern Punjab  Cattle  and  
buffaloes  
Cattle: 105 
Buffaloes: 39  
18.75%   Zulfiqar et al, 
2012  
2012  Ludhiana, Punjab  Cattle  703  1.56%  
B. bigemina  
Singh et al, 2012  
  
2011  9 districts Punjab  411 dairy animals   Cattle: 386 
Buffaloes: 25  
B. bigemina: 2.43% B. 
bigemina + T.  
evansi: 3.41%  
Sharma et al, 2013  
2011  Northern Kerala  
  
Crossbred cattle  150  0.6%  
B. bigemina  
Nair et al, 2011  
2009  Endemic zones of  
Uttar Pradesh and  
Punjab  
Cattle  and  
buffaloes  
Cattle: 180  
Buffaloes: 120  
56.11% SELISA  
23.33% IFAT  
B. bigemina  
Singh et al, 2009  
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No data was found for prevalence of babesiosis.   
  
Myanmar  
Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  
2015  Nation wide  Cattle  713  B. bigemina: 9.8% B. 
bovis: 17.1%  
Bawm et al, 2016  
  
Nepal  
No data was found for prevalence of babesiosis.   
 
Vietnam  
Year  Area  Species of animal  No. of samples 
tested  
% positive  Reference  
2015  Thur Thien  
Hue province  
Cattle and water 
buffaloes  
Cattle: 258 
Buffaloes: 49  
Cattle: 8.9%  
W Buffaloes: 32.65%  
B. bovis  
Yokoyama et al, 
2015  
2014  Central region  Cattle and water 
Buffaloes  
137  PCR:  
B. bovis: 21.3% B. 
bigemina: 16.0% 
ELISA:  
B. bovis: 37.2%  
B. bigemina: 9.3%  
IFAT  
B. bovis: 27.9%  
B. bigemina: 18.6%  
Li et al, 2014  
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Burkina Faso  
Year  Area  Species of 
animal  
No. of samples 
tested  





Cattle  799  B. bigemina  isolated 
from 1 dead calf  








Hue and Hanoi 
provinces  
Cattle, buffalo, 
sheep and goats  
Cattle: 201  
Buffalo: 43  
Sheep: 51  
Goats: 127  
Cattle:  
B. bovis: 8.9% B. 
bigemina: 3.5% 
Buffalo:   
B. bovis: 9.3%  
B. bigemina: 0 Sheep: 
0 for both Goats:  
B. bovis: 0  
B. bigemina: 0.8%  
Sivakumar et al, 
2013  
2008  Around Hanoi  Dairy cattle   239  54% B. bigemina   Geurden et al, 
2008  
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Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  
2015  Around Jimma Town 
South Western 
Ethiopia  




Beishangul Gumuz  
Regional State  
Cattle  402 blood samples  1.5% (blood semar)  Wodajnew et al, 
2015  
2014  Northern Ethipia  Cattle, sheep 
and goats  




Teltele District, North 
West Borena Zone, 
Southern Ethiopia  
Cattle  384 blood samples  Overall: 16.9%  
Fulotole: 9.4%  
Hatuse: 13.6%  
Kulcha: 18.2%  
Billa kebele: 27.85%  




around  Debre-Zeit, 
Central Ethiopia  
Cattle  384 blood smears  0.9%  Sebele et al 2015  
2002  Ghibe Valley  Indigenous 
cattle  
60  Indirect ELISA  
87.1% B. bigemina  
Feleke et al, 2008  
  
Ivory Coast  
Year  Area  Species  of 
animal  
No. of samples 
tested  
% positive  Reference  
2010  Bingerville area  Ticks  from  
36 cattle  
120 Rhipicephalus 
microplus ticks  
Giemsa: 1.73%  Toure et al, 2010  
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Year  Area  Species  of 
animal  
No. of samples 
tested  
% positive  Reference  
2011  Ngong  and  
Machakos  
Cattle  154 Ngong  
38 Machakos  
Ngong:  
B. bigemina: 42.2%  
B. bovis: 12.3%  
Machakos:  
B. bovis: 23.7%  
B. bigemina: 13.2%  
Moumoni et al, 
2015  




Western Kenya  Indigenous 
calves  
548  36% B. bigemina  Kiara et al, 2014  
2007- 
2009  
Western Kenya  Indigenous 
cattle (dams)  
548  48.9%  Toye et al, 2013  
2007- 
2009  
Machakos  Cattle  634 zebu  
15 crossbreds  
563 samples tested:  
38%  B. bigemina  




Western highlands  Cattle  Rural: 600  
Peri-urban: 160  
Rural: 0.42%  
Peri-urban: 1.45%  
Okuthe, 2006  
  
Madagascar  
No recent information on prevalence of babesiosis was found.   
  
Malawi  
No recent information on prevalence of babesiosis was found.   
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Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  
1984  Bamako  Cattle    B. bovis: 38%%  
B. bigemina: 54%  
IFAT  
Miller et al, 1984  
  
Mozambique  
Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  
2010  Maputo Province  Healthy 
cattle  
477  PCR:  
B. bigemina: 30-89%  
B. bovis: 27-83%  
Reverse line blot:  
B. bigemina: 0-17  
B. bovis: 0  
Martins et al, 2010   
2010  Maputo, Gaza and 
Inhambane  
  809  B.bovis: 78.8%  
B. bigemina: 76%  
Tembue et al, 
2011   
2008  Near Maputo city  Cattle  117  PCR  
B. bigemina: 90%  
B. bovis: 82%  
Mixed: 56%  
Martins et al, 2008  
2005  Tete province   Cattle  478  B. bovis: 39%  
  
Alfredo et al, 2005  
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No recent information on prevalence of babesiosis was found.   
  
Senegal  
No recent information on prevalence of babesiosis was found.   
  
South Africa  
Year  Area  Species  of 
animal  
No. of samples 
tested  
% positive  Reference  
2010- 
2012  
All nine provinces of 
South Africa  
Healthy 
cattle  
430  B. bigemina: 64.7  
B. bovis: 35.1  
For details, see table 
below  
Mtshali and  
Mtshali, 2013  
2011  Eight provinces  Healthy 
cattle  
719  B. bovis: 35.3%  
B. bigemina: 39.7%  




Gauteng province  Healthy 
cattle  
268  B. bovis: 35.5%  
B. bigemina: 76.1%  
Mtshali et al, 2013  
  
2010  Northeastern edge  
of the Hluhluwe- 
iMfolozi Park  
Nguni cattle  60  B. bovis: 303%  
B. bigemina: 1.7%  





Ukhahlamba district  
Cattle  200  B. bovis: 45%  
B. bigemina: 46%  




Limpopo  Cattle  30 communal dip 
tanks, and 5  
commercial farms  
B. bovis:  
1999: 63.3%  
2000: 62.4%  
Tonnesen et al, 
2006  
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    B. bigemina:  
1999: 56.1%  















% positive  Reference  
2013  Monduli district  Indigenous cattle  295  B. bovis: 1.7%  Haji et al, 2014  
1999  Tanga and Iringa  Dairy cattle  1,395  B. bovis:  
Tanga: 6%  
Iringa: 12%  
Swai et al, 2004  
1999  2 contrasting regions 
of Tanga (tropical 
Smallholder 
dairy cattle  
1329; ELISA  
test  
Iringa 43%  
Tanga 27%  
Swai et al, 2007  
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coast) and Iringa 
(tropical highlands)  
  
Overall 34.9%  
   
Uganda  
Year  Area  Species of animal  No. of samples 
tested  
% positive  Reference  
2014  Kiruhura district, in 
two sub-counties 
near Lake Mburo 
National Park in  
South-western  
Uganda  
Ankole  Long- 
horned cattle and 
European 
crossbred cattle  
130  26.9%  Schischkle, 2015  
2013- 
2014  
Central  and  
Western Uganda  
Bovine samples  295  B. bigemina: 6.7%  Kasozi et al, 2014  
2008  Kashaari county  Cattle  363  0.6%  Muhanguzi et al, 
2010  
2010  National Parks  Cape buffalo    No Babesia found  Oura et al, 2011  
  
Zambia  
Year  Area  Species of 
animal  
No. of samples 
tested  
% positive  Reference  






Bovine Babesiosis | Monograph 14 






Economic and Social Impacts at Global 







As for other TBD, in Eastern and Southern Africa, as well as in India, the importance and impact of Bovine 
babesiosis is somehow obscured by that of Theileriosis. From the limited studies conducted to date, Minjauw et 
al. [19], quoting a 1999 study, give an estimated annual cost of Bovine Babesiosis in India of   USD 57.2 million.  
Kivaria’s [27] study estimated the combined annual direct costs associated with Babesiosis in Tanzania to be 
45.8million USD, the third most important TBD after ECF and Anaplasmosis. The main components are given in 
the table below.   
Table 6: Combined annual direct cost associated to Babesiosis in Tanzania. [27]  
 
Item  000 000 USD  
Control     
     Acaricides     5.04  
     Chemotherapy    8.60   
Production losses     
     Mortality     21.54  
     Milk loss     1.58  
     Live weight    9.06   
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Makala et al, reported in 2003 that an underestimated number of 200,000 cattle are exposed to bovine 
babesiosis in Zambia. With the high number of naïve B. taurus being introduced in many regions, high 
mortalities are recorded [28].  
According to Bock [5] citing a model developed by McLeod & Kristjanson (1999) in 1999, estimated costs incurred 
due to losses and control of babesiosis and anaplasmosis in Kenya, Zimbabwe, Tanzania, South Africa, China, 
India, Indonesia and Philippines cost 5.1, 5.4, 6.8, 21.6, 19.4, 57.2, 3.1 and 0.6 million US dollars annually, 
respectively  
He states that costs due to babesiosis are incurred not only from mortality, ill-thrift, abortions, loss of milk/meat 
production and draft power and from control measures (such as acaricide treatments, purchase of vaccines and 
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The experience in the US has shown that Babesiosis can be eradicated by eliminating the host tick(s). This was 
accomplished by treating all cattle every 2 to 3 weeks with acaricides (APHIS 2010). In countries where 
eradication is not feasible, tick control can reduce the incidence of disease. The development of resistance to 
acaricides can be a concern. Environmental modification can also destroy tick habitats, but in some cases this 
may be difficult and/ or ecologically undesirable.  
Four methods are available for the control of heartwater: tick control, antibiotic treatment of clinical cases, 
prophylactic use of antibiotics, and immunization. The combination of these 4 methods is also an option. Tick 
control through tick vaccination has been used in Australia [14].   
An important element in the control of bovine babesiosis in endemic regions is the concept of endemic stability.  
  
Endemic stability  
In areas where there is a continuous inoculation of cattle with Babesia spp. by infected ticks, calves are likely to 
be in contact with the parasite during the first 10–12 months of life, when typically they do not show any clinical 
manifestations. Babesia parasites are able to establish persistent infections in these animals that thus develop 
into parasite carriers with strong acquired immunity and resistance to disease [9]. This situation is described as 
enzootic stability; the first description stated that if 75% of the animals in a herd have been exposed to B. bovis 
before 9 months of age, as indicated by specific antibody titres, the chance of observing clinical cases is very low. 
Although natural endemic stability is in principle an ideal condition where no control measures are needed, this 
situation is rare and, when it does exist, it can be easily broken by variations in climate, host genotypes and 
management strategies. In addition, artificially maintaining endemic stability by yearly manipulating 
transmission rates in each herd is highly impractical.   
Importantly, it has been argued that the threshold of 75% exposed cattle as a means to predict the appearance 
of clinical cases should be taken with caution when extrapolated to different regions and host-tick-pathogen 
systems from those on which the model was based [9]. In regions of enzootic instability, or when cattle are 
relocated from tick-free to tick-infested regions, prophylactic immunization has proved an effective method to 
prevent the occurrence of babesiosis outbreaks [5].  
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Vector control   
Eradication of the tick vectors (the so-called minimum disease situation) is the most desirable, permanent 
solution to the problem but is rarely considered practical or economical. The alternative approach, allowing 
natural endemic stability to develop by practicing limited or no tick control, is similarly unrealistic in areas where 
R. appendiculatus and Amblyomma spp. are well established [21]. These regions are also endemic for other 
Rhipicephalus (Boophilus) spp. and essential control of other tick species will inevitably affect the epidemiology 
of redwater. In the long-term, this approach can be achieved by integrating the strategic use of acaricides, the 
application of vaccines in endemically unstable conditions and the use of tick-resistant breeds of cattle [9][21]   
  
Tick vaccine  
A subunit vaccine against R microplus has been developed and commercialized in Australia since 1994, based on 
the Bm86 antigen, and called TickGARD. A similar vaccine, possibly based on the Australian vaccine, has been 
produced in Cuba and commercialized also in parts of South America. The vaccine has been the result of more 
than 12 years of research and field trials with 18,000 cattle.  
While the vaccine is mostly used in an integrated way resulting in reduced reliance on pesticide over years of 
use, Lighthowlers [14] reports that there are observations and studies that have shown:  
• Reduction in incidence of anaplasmosis and babesiosis in Cuba in certain areas (Cuba produces and use the 
tick vaccine),   
• No transmission of B. bigemina and   
• Reduced effect of B. bovis transmitted by R. annulatus on TickGARD-vaccinated cattle  
However, to date, the use of tick vaccine is still limited even in countries where they are produced, except for 
some Latin American countries where the Cuban vaccine is exported. The Australian technology has not been 
exported due to ownership and IP issues.  
  
Treatment  
A number of drugs have been used to date and shown ability to cure infection [9]. Recovery is generally achieved 
if specific treatment is given early in the course of the infection. If treatment is delayed, however, supportive 
therapy may be essential if the animal is to survive. Blood transfusions may be indicated in cattle with heavy 
parasitaemias and low PCVs (<0.10); histo-incompatibility seldom occurs at the first transfusion. In acute B. bovis 
infections, use of antioxidants such as vitamin E, and high doses of corticosteroids may help to offset the 
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hypotensive and hypercoagulable state of the animal. In cases of cerebral babesiosis, intravenous use of 
hypertonic solutions of mannitol or glucose may provide temporary relief.  
Drugs that are successfully used include:  
• Diamidine derivatives: diminazenes (such as Berenil, Trypazen), Amicarbalides, Imidocarb and Phenamidine  
• Quinoline derivatives: quinuronium sulphates (Babesan, Acaprin etc.)  
• Acridine derivatives: Euflavine, Trypan blue  
• Antibiotics: Tetracycline   
Vaccination following the use of chemotherapeutic agents is probably the most frequent cause of vaccine 
failures. The immunity conferred by the live vaccines depends upon the establishment of the infection in the 
host as well as the degree of antigenic stimulation. Chemotherapeutic drugs administered before or during 
babesiosis vaccination will interfere with the multiplication of the parasites and thus the development of 
immunity. The practical implication of this becomes clear when the vaccine is used after the prophylactic 
treatment of cattle with imidocarb, and to a lesser extent, diminazene. The residual effect of these drugs will 
protect the cattle against natural infection for a limited period of time [10]  
This has necessitated the changing of recommended waiting periods before vaccinating with the frozen vaccine 
in the case of B. bovis from 8 to 12 weeks and for B. bigemina from 16 to 24 weeks [10]  
  
Chemoprophylaxis   
Chemoprophylaxis as a method of short-term protection against babesiosis is often used under particular 
instances such as the temporary residence of susceptible animals in an infected area (for example agricultural 
shows), when pregnant cows are at risk and during disease outbreaks.  
Imidocarb and diminazene are the only babesiacides with useful prophylactic properties for the short-term 
control or prevention of babesiosis. Treatment with imidocarb (3 mg/kg) will prevent overt B. bovis infections for 
at least four weeks and B. bigemina infections for at least eight weeks. Diminazene (3,5 mg/kg) will protect 
cattle against the two diseases for one and two weeks, respectively. Unfortunately, the prophylactic use of 
imidocarb may interfere with the development of immunity following vaccinations because the residual effect of 
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Prophylactic immunization has proved most effective to reduce losses caused by bovine babesiosis. Live, 
attenuated strains of B. bovis or B. bigemina are used to vaccinate cattle in some countries. These vaccines have 
safety issues including the potential for virulence in adult animals, possible contamination with other pathogens, 
and hypersensitivity reactions to blood proteins [26]. They are best used in animals less than a year of age to 
minimize the chance of disease. In some cases, vaccination of older cattle is necessary (e.g., if susceptible cattle 
are moved into an endemic area). Older animals should be monitored closely after vaccination, and treated if 
clinical signs develop. In some countries, animals may be vaccinated in the face of an outbreak (OIE Manual). 
The use of genetically resistant cattle such as B. indicus can also decrease the incidence of disease. Natural 
endemic stability is unreliable as the sole control strategy, as it can be affected by climate, host factors and 
management [9].  See more details in Section 6.   
  
Control of outbreaks  
Procedures to be followed during an outbreak will depend largely on the number and manageability of the 
animals concerned, and the availability and cost of labor, drugs, vaccine and acaricides. One or more of the 
following actions can be taken to limit losses:  
• Treat sick animals and separate them, if possible, from the rest of the herd.  
• Have the diagnosis confirmed at a reputable laboratory.  
• Treat unaffected cattle for ticks to prevent exposure.  
• Consider immediate vaccination of all unaffected cattle.  
• Consider use of a prophylactic treatment programme as mentioned above.  
 
Disease situation and government policies by country:   
Tables 7 and 8 below have been completed with the information received so far from the questionnaires sent to 
the DG and DVS.  This information will be updated and completed once the results from the different countries 
are received.   
Table 7 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 7 refers to vaccination.  
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The definitions that were given to the respondents are:  
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination of 
information to those who need to know so that action can be taken.   
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
or within a zone or compartment of that country. 
Table 7:  Official status, official programs for Babesiosis in the countries of interest.  
 




















Bangladesh  Yes  No  No  Yes  Yes  
India            
Indonesia            
Myanmar (Burma)  No  No  No  No  Yes  
Nepal  No  Yes, passive  No  Yes  Yes  
Vietnam  No  No  No  -  -  
AFRICA  
Burkina Faso            
Côte d'Ivoire (Ivory 
Coast)  
Yes  Yes, passive but 
active if  
outbreak  
NO  Yes  If the animals are 
sick  
Ethiopia            
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Kenya  Yes  Yes, passive  No  Yes  Yes  
Madagascar            
Malawi  No  No  Yes  Yes  Yes  
Mali  N/A  N/A  N/A  N/A  N/A  
Mozambique            
Rwanda   -  -  -  -  -  
Senegal            
South Africa            
Tanzania   No  Yes, passive  Yes  Yes  Yes  
Uganda  No  No  No  N/A  N/A  
Zambia            
 
 
Table 8: Vaccination for Babesiosis in the countries of interest. 
 










Who delivers the 
vaccine (official,  
private vaccinators or 
both)  
Species vaccinated  
(cattle, sheep, goats, pigs, 
poultry)  
ASIA      
Bangladesh  No  -  -  -  
India          
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Indonesia          
Myanmar (Burma)  No  -  -  -  
Nepal  No  N/A  N/A  N/A  
Vietnam  No  -  -  -  
AFRICA      
Burkina Faso          
Côte d'Ivoire (Ivory 
Coast)   
No  -  -  -  
Ethiopia          
Kenya  No  Farmers  Both  Cattle  
Madagascar          
Malawi  No  N/A  N/A  N/A  
Mali  N/A  N/A  N/A  N/A  
Mozambique          
Rwanda  -  -  -  -  
Senegal          
South Africa          
Tanzania   No  N/A  N/A  N/A  
Uganda  No  Never vaccinated  N/A  N/A  
Zambia          
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The development of vaccines against bovine babesiosis was prompted by early observations indicating that cows 
that recovered from natural Babesia spp. infections developed long-lasting immunity; and inoculation of their 
blood into susceptible cattle resulted in a less virulent form of the disease. Thus, the first vaccine formulations 
consisted of blood from donor bovines that had recovered from infection [9][10].   
A breakthrough in the development of bovine babesiosis vaccines was achieved by Australian researchers, who 
observed that rapid successive blood passages of B. bovis between splenectomized calves resulted in 
progressive virulence decrease, with diminished post-vaccination changes in body temperature and haematocrit. 
Later, attenuation of B. bigemina was also achieved, but in this case the procedure involved slow successive 
passages among spleen-intact calves [14].  
Attenuation also leads to the waning of nervous symptoms in the case of B. bovis and is sometimes, but not 
always, associated with a loss of tick transmissibility [15]. Since the spleen is important in the trapping and 
destruction of infected erythrocytes, the use of splenectomized bovines yields adequately high parasitaemias in 
the case of B. bovis [5]. Current vaccines against B. bovis and B. bigemina are based on these attenuation 
procedures.  
All currently used vaccines are live attenuated and contain attenuated Australian strains of Babesia, mainly B. 
bovis and B. bigemina (and Anaplasma for some) in a multivalent or monovalent vaccines, and are produced in 
government-supported production facilities as a service to the livestock industries, in particular in Australia, 
USA, Israel, a number of Latin American countries and South Africa (Table 9). Some other countries possess the 
ability to produce vaccine on a smaller scale [6][26].   
Various ways of attenuating Babesia spp. have been reported. The most reliable method of reducing the 
virulence of B. bovis involves rapid passage of the strain through susceptible splenectomised calves. Attenuation 
is not guaranteed, but usually follows after 8 to 20 calf passages [6]. The virulence of B. bigemina decreases 
during prolonged residence of the parasite in latently infected animals. This feature has been used to obtain 
avirulent strains by infecting calves, splenectomising them 6–12 weeks after inoculation and then using the 
ensuing relapse parasites to repeat the procedure [6].  
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Calves to be used as vaccine donors should be splenectomised to allow maximum yield of parasites for 
production of vaccine. This is easier in calves less than 3 months of age and is best performed under general 
anaesthesia [26]. Donor cattle for babesiosis vaccine are bred and maintained tick-free. They should routinely be 
examined for agents of all blood-borne infections prevalent in the country, including Babesia, Anaplasma, 
Theileria, Eperythrozoon and Trypanosoma. The absence of other infective agents endemic in the country, viral, 
bacterial or other, should also be confirmed.  
For the frozen South African vaccine production, the splenectomised calves are infected with attenuated B. 
bigemina or B. bovis vaccine strains, and their heavily infected blood is collected in an anticoagulant at the peak 
of the reactions. The infection is quantified and adjusted by dilution with uninfected whole blood to ensure a 
standardized number of parasites per vaccine dose. To this is added an equal volume of phosphate buffered 
saline diluent containing 20% DMSO as cryoprotectant. Monovalent B. bigemina and B. bovis are produced in 
quantities of five doses each, deep frozen in liquid nitrogen and issued on demand [10].   
The five doses vaccine vials are then stored in liquid nitrogen, while quality control procedures are conducted.  
The released vaccine is then distributed in dry-ice to users in the country.  
Since 1998 there has been an increased preference of the ultra-frozen vaccines over the chilled vaccine [10]. The 
advantages of the frozen vaccines include:   Lower production cost,   
• Prolonged shelf life: chilled live vaccines have limited shelf-life, lasting between 4 and 7 days at 4 °C [5].  
• On demand availability: vaccine can be stored in liquid nitrogen for up to 18 months; this increase cost 
efficiency  
• The pre-release safety and efficacy testing can be conducted while the vaccine is kept frozen  
Live Babesia vaccines are recommended to be used in calves 4 to 10-month-old that generally show good 
tolerance, though a transient clinical response to vaccination can sometimes take place [25]. Adult animals, on the 
other hand, can develop acute babesiosis upon vaccination, for which daily monitoring for up to 21 days is 
suggested and babesiacide treatment is often needed [23][10]. It was observed in South Africa that, after 
chemosterilization of infections, sterile immunity to B. bigemina lasted for only 16 months, without further 
boosting of immunity from tick-acquired infections, while immunity to B. bovis lasted for over 3 years [10]. Thus, 
complete tick control after vaccination is discouraged, so that natural infections through tick bites can aid in the 
acquisition of a long-term protected status [5][10].  
  
The main features of the live Babesia vaccines are as follows [9]:  
• Protective immunity develops in four to six weeks.  
• The immunity lasts for several years in the case of B. bovis, but in the absence of natural challenge, it 
may break down in the case of B. bigemina. However, the latter does not seem to pose a problem under 
endemic conditions and revaccination is therefore rarely advocated.  
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• Babesiosis vaccines can be given at the same time as anaplasmosis and other vaccines, except 
heartwater vaccine.  
• Attenuated strains of B. bovis and B. bigemina impart a high degree of immunity to other strains, even in 
other countries and continents.  
• Factors influencing the development of protective immunity include potency of the vaccine (viability), 
development of ‘breakthrough’ field isolates, poor immunogenicity of the vaccine strain and poor 
responsiveness of the vaccinated animals.  
Table 9 below provides a summary of bovine babesiosis vaccines produced around the world. It is important to 
note that in many cases Bovine Babesiosis vaccines are combined with Anaplasmosis vaccines. Although several 
studies have been published over the years on other forms of Bovine babesiosis vaccine, none have been 
commercialized.   
  
Table 9:   Bovine babesiosis vaccine manufacturers around the world [11] 
 
Country  Vaccine name   Antigen  storage  Reference or contact  
Argentina  
VACUNA CONTRA LA BABESIOSIS Y LA 
ANAPLASMOSIS/INTA-Rafaela  
A. centrale , B. bigemina, 
B bovis   
R    
BIOJAJA/Laboratorio Litoral Biológico  A. centrale , B. bigemina, 





http://www.senasa.gov.ar/contenido.php?to=n&in=1454&io=12690   
VACUNA CONTRA LA BABESIOSIS Y LA  
ANAPLASMOSIS / INTA-Mercedes  
A. centrale , B. bigemina, 




503/at_multi_download/file/INTA_Vacuna Babesiosis y Anaplasmosis 
_Not y com 504.pdftristeza-.-noticias-y-comentarios-
503/at_multi_download/file/ INTA_Vacuna%20Babesiosis%20y%20Anaplas 




ANABASAN®/ Limor de Colombia SA  
A. centrale , B. bigemina, 
B bovis  
U-F  http://corpomail.corpoica.org.co/BACFILES/BACDIGITAL/45107//s2dF1DFA3 
755B2E7DB298E703DD8F72FAF0_1.pdf   
http://www.limorcolombia.com/biotecnologia.html   
USA  Anavac PHL Associates       Anaplasma (Attenuated)  
Australia  
Chilled Tick Fever Vaccine Department of  
Primary Industries and Fisheries, Tick 
Fever  
Centre (DAFF-TFC)  
A. centrale , B. bigemina, 




Fever-Vaccine-Specifications.pdf     
Bovine Babesiosis | Monograph 14 







Combavac 3 in 1 Live Tick Fever Vaccine  A. centrale , B. bigemina, 




Combavac-3-in-1-Live-Tick-Fever-Vaccine-Specifications.pdf    
South 
Africa   
Frozen African Redwater Vaccine for 
Cattle (B. bigemina) Onderstepoort 
Biological Products Ltd. (OBP)  
B.bigemina  U-F    
Frozen Asiatic Redwater Vaccine for 
Cattle (B. havis)  
B. bovis  U-F    
  
Uruguay  
HEMOVAC C / Cibeles  
HEMOVACUNA/ DILAVE Miguel C Rubino   
A. centrale , B. bigemina, 






de%20hemopar%C3%A1sitos.pdf   
Brazil  EMBRAVAC®HEMOPAR/ Hemopar  
ERITROVAC®N2®/Hemopar  
ERITROVAC /Hemopar   
A. centrale , B. bigemina, 





ucts_and_services/arvore/CONT000fmt0bvzi02wyiv8003d0p31bvkqp1.html   
http://www.hemopar.com.br/index.php/produtos.html   
Israel  Kimron Veterinary Institute  A. centrale , B. bigemina, 
B bovis  
U-F    
Mexico  VACUNA CONTRA LA BABESIOSIS 
BOVINA/Cenid-Pavet- INIFAP   
B. bigemina, B bovis  U-F  http://utep.inifap.gob.mx/tecnologias/1.%20Bovinos%20Leche/4.%20Sanid 
ad/VACUNA%20CONTRA%20LA%20BABESIOSIS%20BOVINA.pdf   
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Commercial vaccines manufactured in Africa and Asia  
 
In the countries targeted by the present monograph, only Ondesterpoort Biological Products (OBP) in South 
Africa produces vaccines for B. bovis (commercialised as Frozen Asiatic redwater) and B. bigemina 
(commercialised as Frozen African redwater) (http://www.obpvaccines.co.za/products).  They are both frozen 
vaccines and need to be kept on dry ice or in liquid nitrogen. Once thawed they will be effective for 30 minutes 
to 4 hours depending on the thawing method, and cannot be refrozen for a later use.   
 
Commercial vaccines imported into Africa and Asia 
 
To the best of our knowledge, none of the target countries, in the exception of South Africa, Zambia and to a 
limited extend Mozambique, practices vaccination.   
None of the respondents from the countries of interest, replied that the babesiosis vaccine is being imported 
into their country.   
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Table 10:  Target Product Profile (TPP) Bovine Babesiosis vaccine – Proposal: 
 
 Attribute  Minimum (current available vaccine)  Ideal  
1  Antigen  
  
Immunogen with protective antigens 
of B bigemina or B. bovis that protects 
against respective infections  
Immunogen capable of providing full 
protection in cattle against both B. bovis 
and B. bigemina infections  
2  Indication for use  For active immunization of cattle & 
water buffaloes  
For active immunization of cattle, water 
buffalos and all susceptible animals   
3  Recommended species  
  
Cattle, Water buffaloes  All  B. bovis and B. bigemina susceptible 
animals   
4  Recommended dose  
  
2 ml  1 ml  




vaccine) or ready to use solution 
(inactivated vaccine)  
Ready to use solution/suspension  
6  Route of administration  
  
intramuscular  SC, Intramuscular or pour on  
7  Regimen - primary 
vaccination  
Single dose  Single lifetime dose  
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8  Regimen - booster  Single annual booster  Lifelong immunity after primary 
vaccination  
9  Epidemiological relevance  Protection against all geographically 
distinct strains of B. bovis and B.  
bigemina  
Protection against all geographically 
distinct strains of B. bovis and B.  
bigemina  
10  Recommended age at first 
vaccination  
Animals over 3 months: one injection  
  
From 1-2 months of age   
11  Onset of immunity  
  
2-3 weeks following primary 
vaccination  
One week following primary vaccination  
12  Duration of immunity  
  
At least 1 year  
  
Lifelong immunity  
13  Expected efficacy  To prevent disease & prevent 
mortality.  
To prevent infection and transmission. 
No disease & no mortality in vaccinated 
animals after virulent challenge.  
14  Expected safety  In animals under 6 months of age, a 
transient pyrexia reaction can occur.  A 
transient nodular reaction of varying 
importance, may appear at the 
injection site, it progressively 
disappears within 1 to 2 months.  Only 
vaccinate pregnant animals on 
emergency.  
No post-vaccinal reactions at any age.  
Safe for pregnant animals.   
No carrier form in vaccinated animals  
15  Withdrawal period  
  
Nil  Nil  
16  Special requirements for 
animals  
Do not vaccinate un-healthy animals  Do not vaccinate un-healthy animals 
DIVA  
17  Special requirements for 
persons  
 None  None  
18  Package size  
  
Multiple pack size from 5 doses   Multiple pack size from 5 doses  
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Overall conclusion for improved bovine babesiosis control through vaccination  
 In use over the last 30 to 40 years, live attenuated bovine babesiosis vaccines produced in splenectomised 
animals continue to be the only available form of vaccine to date. While they provide a good protection in 
immunized animals, there wide use is limited due to the complex and risky production process involving live 
animals, the requirement for cold chain and need for close veterinary or specialized supervision during 
administration. The poor results obtained with non-replicating vaccines and the discontinued efforts indicate 
that there may not be an alternative vaccine in the short to medium term.   
None of the Asian countries have been producing or using babesia live attenuated vaccines.   
Options that could be considered in the meantime are:  
1. Further improvement of the current live attenuated vaccine: aspects to be considered would include cell 
culture, freeze-drying, combination of both B.bovis and B.bigemina in Africa.  
2. Given the limited efficacy of inactivated vaccines, a vaccination program consisting of priming with 
inactivated vaccine and boosting with live one could be considered and evaluated as it may address the 
safety problems of the live vaccine, while aiding in the buildup of a solid long lasting immunity  
3. There is a need to consider a broader use of the R. microplus tick vaccine in more regions in Africa and Asia; 
Although there is not yet evidence that the spread of the R. microplus tick in West Africa has corresponded to 
a worsening of Babesiosis, it will be critical to consider starting to deal with the problem before the parasite 
get established    
19  Price to end user  
  
Not more than $0.50/dose  $0.20/dose at end user   
20  Storage condition and shelf-
life as packaged for sale  
12 months at 4-8° C    
  
 24 months 4-8° C and/or 48 hours at  
30° C  
  
21  In-use stability  
  
1 hour  24 hours  
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ANNEX 1:  Additional data on disease presence 
and incidence  
  
Reports to OIE on Babesiosis:  
  
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.   
Babesiosis in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam  
  
Bovine Babesiosis | Monograph 14 






Babesiosis in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal  
  
 Babesiosis in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda  
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Babesiosis in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia  
  
  
 
 
